Sera Prognostics, Inc. (NASDAQ:SERA) Shares Purchased by Sanders Morris Harris LLC

Sanders Morris Harris LLC grew its stake in shares of Sera Prognostics, Inc. (NASDAQ:SERA) by 165.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 90,600 shares of the company’s stock after purchasing an additional 56,500 shares during the quarter. Sanders Morris Harris LLC owned 0.27% of Sera Prognostics worth $725,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Quest Partners LLC lifted its position in Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after acquiring an additional 5,415 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Sera Prognostics during the second quarter worth $68,000. SG Americas Securities LLC purchased a new position in shares of Sera Prognostics in the third quarter valued at $78,000. Prime Capital Investment Advisors LLC acquired a new stake in Sera Prognostics during the 3rd quarter valued at $104,000. Finally, Jane Street Group LLC lifted its holdings in Sera Prognostics by 24.8% in the 3rd quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock worth $111,000 after buying an additional 2,826 shares in the last quarter. Hedge funds and other institutional investors own 54.64% of the company’s stock.

Insider Buying and Selling

In related news, CEO Zhenya Lindgardt sold 12,075 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $7.32, for a total value of $88,389.00. Following the completion of the sale, the chief executive officer now directly owns 819,758 shares of the company’s stock, valued at $6,000,628.56. The trade was a 1.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Austin Aerts sold 7,179 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $7.32, for a total value of $52,550.28. Following the transaction, the chief financial officer now directly owns 291,486 shares in the company, valued at approximately $2,133,677.52. This represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 93,215 shares of company stock worth $666,835. Insiders own 15.80% of the company’s stock.

Sera Prognostics Price Performance

NASDAQ:SERA opened at $6.60 on Thursday. Sera Prognostics, Inc. has a 1-year low of $4.98 and a 1-year high of $12.35. The stock has a market cap of $222.88 million, a P/E ratio of -6.67 and a beta of 0.86. The firm has a 50-day moving average of $7.44 and a two-hundred day moving average of $7.31.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.09 million. During the same quarter in the previous year, the company earned ($0.23) EPS. As a group, equities analysts expect that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.